Skip to Main Content

The Faculty of Medicine - Immunology and Cancer Research: Yefenof Eitan


Last updated September 2023 -  Immunology and Cancer Research

List of Publications

(1) Liu L, Aleksandrowicz E, Schönsiegel F, Gröner D, Bauer N, Nwaeburu CC, et al. Dexamethasone mediates pancreatic cancer progression by glucocorticoid receptor, TGFβ and JNK/AP-1. Cell Death Dis 2017;8(10):e3064.

(2) Kfir-Erenfeld S, Haggiag N, Biton M, Stepensky P, Assayag-Asherie N, Yefenof E. MiR-103 inhibits proliferation and sensitizes hemopoietic tumor cells for glucocorticoid-induced apoptosis. Oncotarget 2017;8(1):472-489.

(3) Schipp C, Nabhani S, Bienemann K, Simanovsky N, Kfir-Erenfeld S, Assayag-Asherie N, et al. Specific antibody deficiency and autoinflammatory disease extend the clinical and immunological spectrum of heterozygous NFKB1 loss-of-function mutations in humans. Haematologica 2016;101(10):e392-e396.

(4) Uzana R, Eisenberg G, Merims S, Frankenburg S, Pato A, Yefenof E, et al. Human T cell crosstalk is induced by tumor membrane transfer. PLoS ONE 2015;10(2).

(5) Kfir-Erenfeld S, Yefenof E. Non-genomic events determining the sensitivity of hemopoietic malignancies to glucocorticoid-induced apoptosis. Cancer Immunol Immunother 2014;63(1):37-43.

(6) Eisenberg G, Uzana R, Pato A, Frankenburg S, Merims S, Yefenof E, et al. Imprinting of lymphocytes with melanoma antigens acquired by trogocytosis facilitates identification of tumor-reactive T cells. J Immunol 2013;190(11):5856-5865.

(7) Yefenof E. T cell mulfunction in the tumor environment. The Tumor Immunoenvironment; 2013. p. 325-338.

(8) Cohen O, Ish-Shalom E, Kfir-Erenfeld S, Herr I, Yefenof E. Nitric oxide and glucocorticoids synergize in inducing apoptosis of CD4+8+ thymocytes: Implications for 'Death by Neglect' and T-cell function. Int Immunol 2012;24(12):783-791.

(9) Sionov RV, Kfir-Erenfeld S, Spokoini R, Yefenof E. A role for Bcl-2 in notch1-dependent transcription in thymic lymphoma cells. Adv Hematol 2012;2012.

(10) Uzana R, Eisenberg G, Sagi Y, Frankenburg S, Merims S, Amariglio N, et al. Trogocytosis is a gateway to characterize functional diversity in melanoma-specific CD8 + T cell clones. J Immunol 2012;188(2):632-640.

(11) Kfir-Erenfeld S, Sionov RV, Spokoini R, Cohen O, Yefenof E. Protein kinase networks regulating glucocorticoid-induced apoptosis of hematopoietic cancer cells: Fundamental aspects and practical considerations. Leuk Lymphoma 2010;51(11):1968-2005.

(12) Eisenberg G, Machlenkin A, Frankenburg S, Mansura A, Pitcovski J, Yefenof E, et al. Transcutaneous immunization with hydrophilic recombinant gp100 protein induces antigen-specific cellular immune response. Cell Immunol 2010;266(1):98-103.

(13) Spokoini R, Kfir-Erenfeld S, Yefenof E, Sionov RV. Glycogen synthase kinase-3 plays a central role in mediating glucocorticoid-induced apoptosis. Mol Endocrinol 2010;24(6):1136-1150.

(14) Cohen O, Kfir-Erenfeld S, Spokoini R, Zilberman Y, Yefenof E, Sionov RV. Nitric oxide cooperates with glucocorticoids in thymic epithelial cell-mediated apoptosis of double positive thymocytes. Int Immunol 2009;21(10):1113-1123.

(15) Izhak L, Wildbaum G, Zohar Y, Anunu R, Klapper L, Elkeles A, et al. A novel recombinant fusion protein encoding a 20-amino acid residue of the third extracellular (E3) domain of CCR2 neutralizes the biological activity of CCL2. J Immunol 2009;183(1):732-739.

(16) Sionov RV, Spokoini R, Kfir-Erenfeld S, Cohen O, Yefenof E. Chapter 6 Mechanisms Regulating the Susceptibility of Hematopoietic Malignancies to Glucocorticoid-Induced Apoptosis. Adv Cancer Res 2008;101:127-248.

(17) Zigmond M, Stabholz A, Shapira J, Bachrach G, Chaushu G, Becker A, et al. Response to Dr S. S. A. Bekhit [2]. J Intellect Disabil Res 2008;52(1):89-90.

(18) Kfir S, Sionov RV, Zafrir E, Zilberman Y, Yefenof E. Staurosporine sensitizes T lymphoma cells to glucocorticoid-induced apoptosis: Role of Nur77 and Bcl-2. Cell Cycle 2007;6(24):3086-3096.

(19) Mizrahi S, Yefenof E, Gross M, Attal P, Yaakov AB, Goldman-Wohl D, et al. A phenotypic and functional characterization of NK cells in adenoids. J Leukocyte Biol 2007;82(5):1095-1105.

(20) Chaushu S, Chaushu G, Zigmond M, Yefenof E, Stabholz A, Shapira J, et al. Age-dependent deficiency in saliva and salivary antibodies secretion in Down's syndrome. Arch Oral Biol 2007;52(11):1088-1096.

(21) Rabinovsky R, Uhr JW, Vitetta ES, Yefenof E. Cancer Dormancy: Lessons from a B Cell Lymphoma and Adenocarcinoma of the Prostate. Adv Cancer Res 2007;97:189-202.

(22) Cervi D, Shaked Y, Haeri M, Usenko T, Lee CR, Haigh JJ, et al. Enhanced natural-killer cell and erythropoietic activities in VEGF-A-overexpressing mice delay F-MuLV-induced erythroleukemia. Blood 2007;109(5):2139-2146.

(23) Zigmond M, Stabholz A, Shapira J, Bachrach G, Chaushu G, Becker A, et al. The outcome of a preventive dental care programme on the prevalence of localized aggressive periodontitis in Down's syndrome individuals. J Intellect Disabil Res 2006;50(7):492-500.

(24) Sionov RV, Kfir S, Zafrir E, Cohen O, Zilberman Y, Yefenof E. Glucocorticoid-induced apoptosis revisited: A novel role for glucocorticoid receptor translocation to the mitochondria. Cell Cycle 2006;5(10):1017-1026.

(25) Sionov RV, Cohen O, Kfir S, Zilberman Y, Yefenof E. Role of mitochondrial glucocorticoid receptor in glucocorticoid-induced apoptosis. J Exp Med 2006;203(1):189-201.

(26) Bachrach G, Chaushu G, Zigmond M, Yefenof E, Stabholz A, Shapira J, et al. Salivary LL-37 secretion in individuals with Down syndrome is normal. J Dent Res 2006;85(10):933-936.

(27) Zilberman Y, Zafrir E, Ovadia H, Yefenof E, Guy R, Sionov RV. The glucocorticoid receptor mediates the thymic epithelial cell-induced apoptosis of CD4+8+ thymic lymphoma cells. Cell Immunol 2004;227(1):12-23.

(28) Guy R, Yefenof E, Naor D, Dorogin A, Zilberman Y. CD44 co-stimulates apoptosis in thymic lymphomas and T cell hybridomas. Cell Immunol 2002;216(1-2):82-92.

(29) Chaushu S, Yefenof E, Becker A, Shapira J, Chaushu G. A link between parotid salivary ig level and recurrent respiratory infections in young Down's syndrome patients. Oral Microbiol Immunol 2002;17(3):172-176.

(30) Chaushu S, Yefenof E, Becker A, Shapira J, Chaushu G. Severe impairment of secretory Ig production in parotid saliva of Down Syndrome individuals. J Dent Res 2002;81(5):308-312.

(31) Yefenof E. Cancer dormancy: From observation to investigation and onto clinical intervention. Semin Cancer Biol 2001;11(4):269-270.

(32) Yefenof E. Complement receptor 3 (CR3): A public transducer of innate immunity signals in macrophages. Adv Exp Med Biol 2000;479:15-25.

(33) Clinchy B, Gazdar A, Rabinovsky R, Yefenof E, Gordon B, Vitetta ES. The growth and metastasis of human, HER-2/neu-overexpressing tumor cell lines in male SCID mice. Breast Cancer Res Treat 2000;61(3):217-228.

(34) Rosenheimer-Goudsmid N, Haupt Y, Yefenof E, Zilberman Y, Guy R. p53 and thymic 'death by neglect': Thymic epithelial cell-induced apoptosis of CD4+8+ thymocytes is p53-independent. Cell Death Differ 2000;7(3):241-249.

(35) Zilberman Y, Yefenof E, Katzav S, Dorogin A, Rosenheimer-Goudsmid N, Guy R. Apoptosis of thymic lymphoma clones by thymic epithelial cells: A putative model for 'death by neglect'. Immunol Lett 1999;67(2):95-104.

(36) Yefenof E. Murine models of thymic lymphomas: premalignant scenarios amenable to prophylactic therapy. Adv Immunol 1999;73(73):511-539.

(37) Avni O, Pur Z, Yefenof E, Baniyash M. Complement receptor 3 of macrophages is associated with galectin-1-like protein. J Immunol 1998;160(12):6151-6158.

(38) Yefenof E. Apoptosis in the immune system and cancer: Common denominators and bilateral implications. Biotherapy (Japan) 1998;12(1):1-5.

(39) Epzsteyn S, Vitetta ES, Yefenof E. Prophylactic intervention in RadL V-induced lymphomagenesis with an anti-IL-4 monoclonal antibody. J Immunother 1997;20(4):287-291.

(40) Zilberman Y, Yefenof E, Oron E, Dorogin A, Guy R. T cell receptor-independent apoptosis of thymocyte clones induced by a thymic epithelial cell line is mediated by steroids. Cell Immunol 1996;170(1):78-84.

(41) Chaushu G, Chaushu S, Slavin S, Or R, Garfunkel AA, Yefenof E. Salivary immunoglobulins in recipients of bone marrow grafts III. A longitudinal follow-up of CMV specific antibodies. Bone Marrow Transplant 1996;17(2):237-241.

(42) Guy R, Gafanovich I, Rosenheimer N, Oron E, Yefenof E, Zilberman Y. MHC non-restricted, CD95-independent apoptosis of immature thymocytes induced by thymic epithelial cells. Cell Death Differ 1996;3(4):431-438.

(43) Yefenof E, Gafanovitch I, Oron E, Bar M, Klein E. Prophylactic intervention in radiation-leukemia-virus-induced murine lymphoma by the biological response modifier polysaccharide K. Cancer Immunol Immunother 1995;41(6):389-396.

(44) Racila E, Scheuermann RH, Picker LJ, Yefenof E, Tucker T, Chang W, et al. Tumor dormancy and cell signaling. II. Antibody as an agonist in inducing dormancy of a B cell lymphoma in SCID mice. J Exp Med 1995;181(4):1539-1550.

(45) Avni O, Yefenof E, Kotler M. Clonal dominance of RadLV-induced lymphomas. Leuk Res 1995;19(12):971-976.

(46) Chaushu G, Itzkovitz-Chaushu S, Yefenof E, Slavin S, Or R, Garfunkel AA. A longitudinal follow-up of salivary secretion in bone marrow transplant patients. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 1995;79(2):164-169.

(47) Messika EJ, Avni O, Gallily R, Yefenof E, Baniyash M. Identification and characterization of a novel protein associated with macrophage complement receptor 3. J Immunol 1995;154(12):6563-6570.

(48) Yefenof E, Kotler M. Radiation leukemia virus-induced leukemogenesis: A paradigm of preleukemia and its control by preventive therapy. ADV CANCER RES 1995;66:293-312.

(49) Chaushu S, Chaushu G, Garfunkel A, Slavin S, Or R, Yefenof E. Salivary immunoglobulins in recipients of bone marrow grafts. II. Transient secretion of donor-derived salivary IgA following transplantation of T cell-depleted bone marrow. Bone Marrow Transplant 1994;14(6):925-928.

(50) Chaushu S, Chaushu G, Garfunkel AA, Slavin S, Or R, Yefenof E. Salivary immunoglobulins in recipients of bone marrow grafts. I. A longitudinal follow-up. Bone Marrow Transplant 1994;14(6):871-876.

(51) Yefenof E, Magyariakl T, Fenyo E, Wahren B, Klein E. Alternative complement pathway activation by CD4+ T cells of HIV infected individuals: A possible role in AIDS pathogenesis. Int Immunol 1994;6(9):1361-1366.

(52) Kotler M, Ruchlemer R, Avni O, Yefenof E. Radiation leukemogenesis: Quantitative relationship between pre‐leukemic cells in the thymus and lymphoma induction. Int J Cancer 1994;56(5):761-765.

(53) Scheuermann RH, Racila E, Tucker T, Yefenof E, Street NE, Vitetta ES, et al. Lyn tyrosine kinase signals cell cycle arrest but not apoptosis in B- lineage lymphoma cells. Proc Natl Acad Sci U S A 1994;91(9):4048-4052.

(54) Yefenof E, Picker LJ, Scheuermann RH, Tucker TF, Vitetta ES, Uhr JW. Cancer dormancy: Isolation and characterization of dormant lymphoma cells. Proc Natl Acad Sci U S A 1993;90(5):1829-1833.

(55) Yefenof E, Picker LJ, Scheuermann RH, Vitetta ES, Street NE, Tucker TF, et al. Induction of B cell tumor dormancy by anti-idiotypic antibodies. Curr Opin Immunol 1993;5(5):740-744.

(56) Guy R, Yefenof E, Zilberman Y. Mitogenic activation of phosphoinositide turnover and DNA synthesis in murine CD4+8+ thymocytes. Immunol Lett 1993;36(3):251-260.

(57) Kuraya M, Klein G, Klein E, Yefenof E. Expression of the complement regulatory proteins CD21, CD55 and CD59 on Burkitt lymphoma lines: their role in sensitivity to human serum‐mediated lysis. Eur J Immunol 1992;22(7):1871-1876.

(58) Yefenof E, Ela C, Kotler M, Vitetta ES. Induction of IL‐4 secretion by the radiation leukemia virus (RadLV): Role in autocrine growth stimulation of RadLV infected pre‐leukemic cells. Int J Cancer 1992;50(3):481-485.

(59) Yefenof E, Abboud G, Epszteyn S, Vitetta ES. Treatment of premalignancy: Prevention of lymphoma in radiation leukemia virus-inoculated mice by cyclosporin A and immunotoxin. Proc Natl Acad Sci U S A 1992;89(2):728-732.

(60) Naftalovich S, Yefenof E, Eilam Y. Antitumor effects of ketoconazole and trifluoperazine in murine T-cell lymphomas. Cancer Chemother Pharmacol 1991;28(5):384-390.

(61) Yefenof E, Epszteyn S, Kotler M. Quantitation, in Vitro Propagation, and Characterization of Preleukemic Cells Induced by Radiation Leukemia Virus. Cancer Res 1991;51(8):2179-2184.

(62) Yefenof E, åsjö B, Klein E. Alternative complement pathway activation by HIV infected cells: C3 fixation does not lead to complement lysis but enhances NK sensitivity. Int Immunol 1991;3(4):395-401.

(63) Yefenof E, Einat E, Klein E. Potentiation of T cell immunity against radiation-leukemia-virus-induced lymphoma by polysaccharide K. Cancer Immunol Immunother 1991;34(2):133-137.

(64) Yefenof E, Algarra I, Ramos OF, Klein E. Activation and fixation of C3 by human B cell lines is enhanced by interferon-gamma and tumor necrosis factor alpha. Complement Inflamm 1991;8(5-6):271-280.

(65) Laskov R, Michaeli R‐, Sharir H, Yefenof E, Vlodavsky I. Production of heparanase by normal and neoplastic murine B‐lymphocytes. Int J Cancer 1991;47(1):92-98.

(66) Messika E, Gallily R, Yefenof E. Radiation leukemia virus (RadLV)‐induced leukemogenesis is associated with an increased number and activity of thymic macrophages. Int J Cancer 1991;48(6):924-930.

(67) Di Renzo L, Yefenof E, Klein E. The function of human NK cells is enhanced by β‐glucan, a ligand of CR3 (CD11b/CD18). Eur J Immunol 1991;21(7):1755-1758.

(68) Klein E, Renzo LD, Yefenof E. Contribution of CR3, CD11b/CD 18 to cytolysis by human NK cells. Mol Immunol 1990;27(12):1343-1347.

(69) Yefenof E, Benizri R, Reiter Y, Klein E, Fishelson Z. Potentiation of NK cytotoxicity by antibody-C3b/iC3b heteroconjugates. J Immunol 1990;144(4):1538-1543.

(70) Yefenof E, Zehavi‐Feferman R, Guy R. Control of primary and secondary antibody responses by cytotoxic T lymphocytes specific for a soluble antigen. Eur J Immunol 1990;20(8):1849-1853.

(71) Yefenof E, Ramos OF, Nilsson B, Klein E. Ligands of CR2 do not interfere with C3 fragment fixation or enhanced NK sensitivity of Raji cells treated with human serum. Immunol Lett 1989;21(4):303-306.

(72) Ramos OF, Algarra I, Sarmay G, Yefenof E, Gergely J, Klein E. Lymphocytes stimulated by allogeneic B cell lines cleave the third component of complement and fix C3 fragments. Their nonspecific lytic capacity is elevated against complement receptor type 2-carrying targets. J Immunol 1989;142(1):217-223.

(73) Ramos OF, Nilsson B, Nilsson K, Eggertsen G, Yefenof E, Klein E. Elevated NK-mediated lysis of Raji and Daudi cells carrying fixed iC3b fragments. Cell Immunol 1989;119(2):459-469.

(74) Sprecher E, Giloh H, Rahamim E, Yefenof E, Becker Y. Cytofluorometric analysis of thymic interdigitating cells from C57BL/6 mice prior and after leukemogenic X-irradiation. Leuk Res 1989;13(9):799-809.

(75) Ramos OF, Patarroyo M, Yefenof E, Klein E. Requirement of leukocytic cell adhesion molecules (CD11a-c/CD18) in the enhanced NK lysis of iC3b-opsonized targets. J Immunol 1989;142(11):4100-4104.

(76) Yefenof E, Ben-David Y, Kotler M. Preleukemic cells induced by RadLV are of an oligoclonal nature. Leukemia 1988;2(12 SUPPL.):97s-101s.

(77) Kai C, Sármay G, Ramos O, Yefenof E, Klein E. Elevated NK sensitivity of Raji cells carrying acceptor-bound C3 fragments. Cell Immunol 1988;113(2):227-234.

(78) Bakacs T, Totpal K, Ringwald G, Yefenof E. Comparison of monocyte and complement mediated haemolysis of human A1 erythrocytes: the relationship between antibody, target and effector concentrations in the induction of lysis. J Clin Lab Immunol 1988;25(2):53-58.

(79) Ramos OF, Kai C, Yefenof E, Klein E. The elevated natural killer sensitivity of targets carrying surface-attached C3 fragments require the availability of the iC3b receptor (CR3) on the effectors. J Immunol 1988;140(4):1239-1243.

(80) Klein E, Ramos O, Sármay G, Yefenof E, Gergely J. Lysis of CR2-carrying cells by natural killer cells and by activated T-lymphocytes is enhanced by C3 fragments. Mol Immunol 1988;25(11):1063-1066.

(81) Yefenof E, Klein E. The third component of complement (C3) and its contribution to the immune response. Harefuah 1987;113(7-8):175-177.

(82) Myers CD, Sanders VM, Yefenof E, Oliver KG, Uhr JW, Vitetta ES. Purification and Characterization of Antigen-Binding Virgin and Memory B Cells. Methods Enzymol 1987;150(C):316-325.

(83) David YB, Kotler M, Yefenof E. A highly leukemogenic radiation leukemia virus isolate is a thymotropic, immunosuppressive retrovirus with a unique rna structure. Int J Cancer 1987;39(4):492-497.

(84) Klein E, Sármay G, Ramos O, Yefenof E, Gergely J. Contribution of activated C3 to lymphocyte-mediated cytolysis. Mol Immunol 1986;23(11):1257-1262.

(85) Yefenof E, Sanders VM, Uhr JW, Vitetta ES. In vitro activation of murine antigen-specific memory B cells by a T-dependent antigen. J Immunol 1986;137(1):85-90.

(86) Yefenof E, Ben-David Y. Immunity and suppression in radiation- and radiation leukemia virus (RadLV)-induced leukemogenesis. Leuk Res 1986;10(7):797-801.

(87) Yefenof E, Sanders VM, Snow EC, Noelle RJ, Oliver KG, Uhr JW, et al. Preparation and analysis of antigen-specific memory B cells. J Immunol 1985;135(6):3777-3784.

(88) Yefenof E, McConnell I. Interferon amplifies complement activation by Burkitt's lymphoma cells. Nature 1985;313(6004):684-685.

(89) Ramos OF, Sarmay G, Klein E, Yefenof E, Gergely J. Complement-dependent cellular cytotoxicity: Lymphoblastoid lines that activate complement component 3 (C3) and express C3 receptors have increased sensitivity to lymphocyte-mediated lysis in the presence of fresh human serum. Proc Natl Acad Sci U S A 1985;82(16):5470-5474.

(90) Yefenof E, Feinmani R, Kedar E. Antigen non-specific activities in culture supernatant of ovalbumin-specific, cloned helper T lymphoma. Immunobiology 1985;169(5):520-531.

(91) Yefenof E, David YB, Kotler M. High‐ and low‐leukemogenic variants of the radiation leukemia virus (RadLV): Immunogenic, suppressive and genetic properties in relation to leukemogenic activity. Int J Cancer 1984;34(6):875-882.

(92) Yefenof E, Klein E, Yron I. Contribution of activated C3 to lymphocyte-mediated target lysis: Complement-dependent cellular cytotoxicity. Mol Immunol 1984;21(12):1211-1214.

(93) Yefenof E, Yron I, Klein E. Complement-dependent cellular cytotoxicity due to alternative pathway C3 activation by the target cell membrane. Cell Immunol 1984;87(2):698-702.

(94) Yefenof E, Ben-David Y. Suppressor and reactive lymphocytes in radiation leukemia virus (RadLV)-induced leukemogenesis. Cancer Immunol Immunother 1983;16(1):48-52.

(95) Yefenof E, Schwartz S, Katz-Gross A. Increased humoral and cellular immunity in mice inoculated with allogeneic tumor cells attached to microcarrier beads. Immunol Lett 1983;6(1):39-43.

(96) Yefenof E, Azar Y, Eidelsztein P, Ben-Sasson SZ. Immortalization of antigen specific, helper T cell lines by transformation with the radiation leukemia virus (RadLV). J Immunol 1982;128(2):625-628.

(97) Yefenof E, Goldapfel M, Ber R. Nonimmunogenic radiation induced lymphoma immunity induction by a somatic cell hybrid. J Natl Cancer Inst 1982;68(5):841-849.

(98) Yefenof E, Zilcha D. High‐ and low‐leukemogenic variants of the radiation leukemia virus (RadLV) differ in ability to induce tumor‐specific immune suppression. Int J Cancer 1982;30(3):355-359.

(99) Azar Y, Eidelsztein P, Yefenof E, Chriqui E, Katz-Gross A, Kedar E, et al. Antigen-specific murine T-cell lymphomas: Functional heterogenicity. Cell Immunol 1981;65(1):194-200.

(100) Yefenof E, Meidav A, Kedar E. In vitro generation of cytotoxic lymphocytes against radiation- and radiation leukemia virus-induced tumors: III. Suppression of anti-tumor immunity in vitro by lymphocytes of mice undergoing radiation leukemia virus-induced leukemogenesis. J Exp Med 1980;152(6):1473-1483.

(101) Yefenof E. In vitro generation of cytotoxic lymphocytes against radiation and radiation leukaemia virus-induced tumors. II. A radiation-induced thymoma generates cytotoxic response in syngeneic but not in allogeneic lymphocytes. Immunology 1980;41(1):99-106.

(102) Yefenof E, Tchakirov R, Kedar E. In vitro generation of cytotoxic lymphocytes against radiation and radiation leukemia virus-induced tumors - I. Role of viral antigenicity. Cancer Immunol Immunother 1980;8(2-3):171-178.

(103) Schulz T, Dierich MP, Yefenof E, Klein G. C3-Activating proteases on human lymphoblastoid cells superinfected with epstein-barr virus. Cell Immunol 1980;51(1):168-172.

(104) Karande A, Yefenof E, Fenyö EM, Klein G. Moloney lymphoma cells express a polyprotein contanining the GAG gene‐coded p15 and the moloney leukemia virus‐induced cell surface antigen (MCSA). Int J Cancer 1979;23(4):508-513.

(105) Polliack A, Yefenof E, Gamliel H, Klein G. Burkitt's lymphoma cells: Membrane properties and surface morphology as seen by scanning electron microscopy. Leuk Res 1979;3(4):217-221,223-225.

(106) Dierich MP, Schulz T, Yefenof E, Kiein G. Detection of proteolytic (C 3‐cleaving) activity on mouse mastocytoma (P815) cells and other mouse cell lines by formation of cell contact with C 3‐carrying mouse lymphocytes. Eur J Immunol 1979;9(12):928-932.

(107) Yefenof E. Epstein Barr virus (EBV) and complement (C3) interactions with human lymphoid cells. Haematol Blood Transfus 1979;23:237-238.

(108) Viallat J, Svedmyr E, Yefenof E, Klein G, Weiland O. Stimulation of human peripheral blood lymphocytes by autologous EBV-infected B cells. Cell Immunol 1978;41(1):1-8.

(109) Ber R, Klein G, Moar M, Rosén A, Westman A, Yefenof E, et al. Somatic cell hybrids between human lymphoma lines. IV. Establishment and characterization of a p3HR‐1/daudi hybrid. Int J Cancer 1978;21(6):707-719.

(110) Steinitz M, Bakács T, Yefenof E, Klein G. Inhibition of dna metabolism in human b lymphocytes by a substrain of epstein-barr virus (P3hr-1): A method for virus quantitation. Intervirology 1978;10(2):125-131.

(111) Yefenof E, Lundin L, Klein G. Shedding of anti‐IgM from antibody‐coated human lymphoma lines: Differences between Epstein‐Barr virus‐negative lines and their virus‐converted sublines. Eur J Immunol 1978;8(3):190-193.

(112) Bakacs T, Klein E, Yefenof E, Gergely P, Steinitz M. Human blood lymphocyte fractionation with special attention to their cytotoxic potential. Z IMMUNITATSFORSCH 1978;154(2):121-134.

(113) Yefenof E, Bakacs T, Einhorn L, Ernberg I, Klein G. Epstein-Barr virus (EBV) receptors, complement receptors, and EBV infectibility of different lymphocyte fractions of human peripheral blood. I. Complement receptor distribution and complement binding by separated lymphocyte subpopulations. Cell Immunol 1978;35(1):34-42.

(114) Einhorn L, Steinitz M, Yefenof E, Ernberg I, Bakacs T, Klein G. Epstein-Barr virus (EBV) receptors, complement receptors, and EBV infectibility of different lymphocyte fractions of human peripheral blood. II. Epstein-Barr virus studies. Cell Immunol 1978;35(1):43-58.

(115) Fenyö EM, Yefenof E, Klein E, Klein G. Immunization of mice with syngeneic moloney lymphoma cells induces separate antibodies against virion envelope glycoprotein and virus-induced cell surface antigens*. J Exp Med 1977;146(6):1521-1533.

(116) Yefenof E, Klein G, Kvarnung K. Relationships between complement activation, complement binding, and EBV absorption by human hematopoietic cell lines. Cell Immunol 1977;31(2):225-233.

(117) Yefenof E, Klein G, Ben-Bassat H, Lundin L. Differences in the ConA-induced redistribution and agglutination patterns of EBV genome-free and EBV-carrying human lymphoma lines. Exp Cell Res 1977;108(1):185-190.

(118) Yefenof E, Klein G. Membrane receptor stripping confirms the association between ebv receptors and complement receptors on the surface of human b lymphoma lines. Int J Cancer 1977;20(3):347-352.

(119) Klein E, Neumann H, Steinitz M, Yefenof E. Epstein Barr Virus (EBV) determined characteristics in lymphoid cells. Bibl Haematol 1976;No.43:13-18.

(120) JONDAL M, KLEIN G, OLDSTONE MBA, BOKISH V, YEFENOF E. Surface Markers on Human B and T Lymphocytes: VIII. Association Between Complement and Epstein‐Barr Virus Receptors on Human Lymphoid Cells. Scand J Immunol 1976;5(4):401-410.

(121) Yefenof E, Klein G, Jondal M, Oldstone MBA. Surface markers on human B‐ and T‐lymphocytes. IX. Two‐color immunofluorescence studies on the association between EBV receptors and complement receptors on the surface of lymphoid cell lines. Int J Cancer 1976;17(6):693-700.

(122) Yefenof E, Klein G. Difference in antibody induced redistribution of membrane IgM in EBV-genome free and EBV positive human lymphoid cells. Exp Cell Res 1976;99(1):175-178.

(123) Yefenof E, Witz IP, Klein E. Interaction of antibody and cell surface localized antigen. Int J Cancer 1976;17(5):633-639.

(124) JONDAL M, KLEIN E, YEFENOF E. Surface Markers on Human B and T Lymphocytes: VII. Rosette Formation Between Peripheral T Lymphocytes and Lymphoblastoid B‐Cell Lines. Scand J Immunol 1975;4(3):259-266.

(125) Killander D, Yefenof E, Klein E. Antibody-induced redistribution of surface antigen is independent of the amount of antigen and the cell cycle position. Exp Cell Res 1974;89(2):413-415.

(126) Yefenof E, Klein G. Antibody-induced redistribution of normal and tumor associated surface antigens. Exp Cell Res 1974;88(2):217-224.